Literature DB >> 25096061

Transcriptional regulation of STAT3 by SPTBN1 and SMAD3 in HCC through cAMP-response element-binding proteins ATF3 and CREB2.

Ling Lin1, Zhixing Yao1, Krithika Bhuvaneshwar2, Yuriy Gusev2, Bhaskar Kallakury1, Shaoxian Yang1, Kirti Shetty1, Aiwu Ruth He3.   

Abstract

The cytoskeletal protein Spectrin, beta, non-erythrocytic 1 (SPTBN1), an adapter protein to SMAD3 in TGF-β signaling, may prevent hepatocellular carcinoma (HCC) development by downregulating the expression of signal transducer and activator of transcription 3 (STAT3). To elucidate the as yet undefined mechanisms that regulate this process, we demonstrate that higher levels of STAT3 transcription are found in livers of heterozygous SPTBN1(+/-) mice as compared to that of wild type mice. We also found increased levels of STAT3 mRNA, STAT3 protein, and p-STAT3 in human HCC cell-lines after knockdown of SPTBN1 or SMAD3, which promoted cell colony formation. Inhibition of STAT3 overrode the increase in cell colony formation due to knockdown of SPTBN1 or SMAD3. We also found that inhibition of SPTBN1 or SMAD3 upregulated STAT3 promoter activity in HCC cell-lines, which is dependent upon the cAMP-response element (CRE) and STAT-binding element (SBE) sites of the STAT3 promoter. Mechanistically, suppression of SPTBN1 and SMAD3 augmented the transcription of STAT3 by upregulating the CRE-binding proteins ATF3 and CREB2 and augmented the binding of those proteins to the regions within or upstream of the CRE site of the STAT3 promoter. Finally, in human HCC tissues, SPTBN1 expression correlated negatively with expression levels of STAT3, ATF3, and CREB2; SMAD3 expression correlated negatively with STAT3 expression; and the level of phosphorylated SMAD3 (p-SMAD3) correlated negatively with ATF3 and CREB2 protein levels. SPTBN1 and SMAD3 collaborate with CRE-binding transcription factors to inhibit STAT3, thereby preventing HCC development.
© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25096061     DOI: 10.1093/carcin/bgu163

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  16 in total

Review 1.  Who regulates whom: ZNF341 is an additional player in the STAT3/TH17 song.

Authors:  Avery August
Journal:  Sci Immunol       Date:  2018-06-15

2.  βIV-Spectrin regulates STAT3 targeting to tune cardiac response to pressure overload.

Authors:  Sathya D Unudurthi; Drew Nassal; Amara Greer-Short; Nehal Patel; Taylor Howard; Xianyao Xu; Birce Onal; Tony Satroplus; Deborah Hong; Cemantha Lane; Alyssa Dalic; Sara N Koenig; Adam C Lehnig; Lisa A Baer; Hassan Musa; Kristin I Stanford; Sakima Smith; Peter J Mohler; Thomas J Hund
Journal:  J Clin Invest       Date:  2018-11-12       Impact factor: 14.808

3.  Identification of Prognostic Glycolysis-Related lncRNA Signature in Tumor Immune Microenvironment of Hepatocellular Carcinoma.

Authors:  Yang Bai; Haiping Lin; Jiaqi Chen; Yulian Wu; Shi'an Yu
Journal:  Front Mol Biosci       Date:  2021-04-22

4.  G-DOC Plus - an integrative bioinformatics platform for precision medicine.

Authors:  Krithika Bhuvaneshwar; Anas Belouali; Varun Singh; Robert M Johnson; Lei Song; Adil Alaoui; Michael A Harris; Robert Clarke; Louis M Weiner; Yuriy Gusev; Subha Madhavan
Journal:  BMC Bioinformatics       Date:  2016-04-30       Impact factor: 3.169

5.  Long non-coding RNA00364 represses hepatocellular carcinoma cell proliferation via modulating p-STAT3-IFIT2 signaling axis.

Authors:  Wei-Guo Tang; Bo Hu; Hai-Xiang Sun; Qi-Man Sun; Chao Sun; Pei-Yao Fu; Zhang-Fu Yang; Xin Zhang; Chen-Hao Zhou; Jia Fan; Ning Ren; Yang Xu
Journal:  Oncotarget       Date:  2017-10-25

6.  ZNF341 controls STAT3 expression and thereby immunocompetence.

Authors:  Stefanie Frey-Jakobs; Julia M Hartberger; Manfred Fliegauf; Claudia Bossen; Magdalena L Wehmeyer; Johanna C Neubauer; Alla Bulashevska; Michele Proietti; Philipp Fröbel; Christina Nöltner; Linlin Yang; Jessica Rojas-Restrepo; Niko Langer; Sandra Winzer; Karin R Engelhardt; Cristina Glocker; Dietmar Pfeifer; Adi Klein; Alejandro A Schäffer; Irina Lagovsky; Idit Lachover-Roth; Vivien Béziat; Anne Puel; Jean-Laurent Casanova; Bernhard Fleckenstein; Stephan Weidinger; Sara S Kilic; Ben-Zion Garty; Amos Etzioni; Bodo Grimbacher
Journal:  Sci Immunol       Date:  2018-06-15

7.  SPTBN1 suppresses the progression of epithelial ovarian cancer via SOCS3-mediated blockade of the JAK/STAT3 signaling pathway.

Authors:  Mo Chen; Jia Zeng; Shuyi Chen; Jiajia Li; Huijie Wu; Xuhui Dong; Yuan Lei; Xiuling Zhi; Liangqing Yao
Journal:  Aging (Albany NY)       Date:  2020-06-08       Impact factor: 5.682

8.  ATF3 Sustains IL-22-Induced STAT3 Phosphorylation to Maintain Mucosal Immunity Through Inhibiting Phosphatases.

Authors:  Doaa Glal; Janaki N Sudhakar; Hsueh-Han Lu; Ming-Che Liu; Hung-Yu Chiang; Yen-Chun Liu; Ching-Feng Cheng; Jr-Wen Shui
Journal:  Front Immunol       Date:  2018-11-05       Impact factor: 7.561

Review 9.  Master Regulator Activating Transcription Factor 3 (ATF3) in Metabolic Homeostasis and Cancer.

Authors:  Hui-Chen Ku; Ching-Feng Cheng
Journal:  Front Endocrinol (Lausanne)       Date:  2020-08-14       Impact factor: 5.555

Review 10.  Emerging therapeutic targets for cardiac arrhythmias: role of STAT3 in regulating cardiac fibroblast function.

Authors:  Nehal J Patel; Drew M Nassal; Daniel Gratz; Thomas J Hund
Journal:  Expert Opin Ther Targets       Date:  2020-11-23       Impact factor: 6.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.